147 related articles for article (PubMed ID: 9024675)
21. Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset.
Makowska JM; Bonner FW; Gibson GG
Arch Toxicol; 1991; 65(2):106-13. PubMed ID: 1905530
[TBL] [Abstract][Full Text] [Related]
22. Incidence of pancreatic and testicular tumors in rats treated with ciprofibrate, a peroxisome proliferator.
Rao MS; Subbarao V
Cancer Lett; 1995 Nov; 97(2):185-8. PubMed ID: 7497461
[TBL] [Abstract][Full Text] [Related]
23. Genotoxic effects of selected peroxisome proliferators.
Reisenbichler H; Eckl PM
Mutat Res; 1993 Apr; 286(2):135-44. PubMed ID: 7681524
[TBL] [Abstract][Full Text] [Related]
24. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
Awasthi YC; Singh SV; Goel SK; Reddy JK
Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.
Rao MS; Lalwani ND; Watanabe TK; Reddy JK
Cancer Res; 1984 Mar; 44(3):1072-6. PubMed ID: 6692393
[TBL] [Abstract][Full Text] [Related]
26. Comparison of constitutive and inducible levels of expression of peroxisomal beta-oxidation and catalase genes in liver and extrahepatic tissues of rat.
Nemali MR; Usuda N; Reddy MK; Oyasu K; Hashimoto T; Osumi T; Rao MS; Reddy JK
Cancer Res; 1988 Sep; 48(18):5316-24. PubMed ID: 2900680
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferation and beta-oxidation in Fao and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: effect of ciprofibrate.
Duclos S; Bride J; Ramirez LC; Bournot P
Eur J Cell Biol; 1997 Apr; 72(4):314-23. PubMed ID: 9127731
[TBL] [Abstract][Full Text] [Related]
28. Response of genetically obese Zucker rats to ciprofibrate, a hypolipidemic agent, with peroxisome proliferation activity as compared to Zucker lean and Sprague-Dawley rats.
Pacot C; Petit M; Caira F; Rollin M; Behechti N; Grégoire S; Cherkaoui Malki M; Cavatz C; Moisant M; Moreau C
Biol Cell; 1993; 77(1):27-35. PubMed ID: 8518742
[TBL] [Abstract][Full Text] [Related]
29. Effects of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cellular antioxidants and lipid peroxidation in rats.
Glauert HP; Srinivasan S; Tatum VL; Chen LC; Saxon DM; Lay LT; Borges T; Baker M; Chen LH; Robertson LW
Biochem Pharmacol; 1992 Mar; 43(6):1353-9. PubMed ID: 1562286
[TBL] [Abstract][Full Text] [Related]
30. Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate.
Yadetie F; Laegreid A; Bakke I; Kusnierczyk W; Komorowski J; Waldum HL; Sandvik AK
Physiol Genomics; 2003 Sep; 15(1):9-19. PubMed ID: 12851464
[TBL] [Abstract][Full Text] [Related]
31. Comparative and simultaneous effects of simvastatin and ciprofibrate on plasma lipid parameters and upon hepatic drug metabolizing and peroxisome proliferation marker enzymes in the male Wistar rat.
Charmoillaux M; Goudonnet H; Mercenne F; Mounié J; Truchot RC
Cell Mol Biol; 1991; 37(8):765-71. PubMed ID: 1807786
[TBL] [Abstract][Full Text] [Related]
32. Peroxisome proliferator-induced alterations in the expression and modification of rat hepatocyte plasma membrane proteins.
Bartles JR; Khuon S; Lin XH; Zhang LQ; Reddy JK; Rao MS; Isoye ST; Nehme CL; Fayos BE
Cancer Res; 1990 Feb; 50(3):669-76. PubMed ID: 2404574
[TBL] [Abstract][Full Text] [Related]
33. Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years.
Graham MJ; Wilson SA; Winham MA; Spencer AJ; Rees JA; Old SL; Bonner FW
Fundam Appl Toxicol; 1994 Jan; 22(1):58-64. PubMed ID: 8125214
[TBL] [Abstract][Full Text] [Related]
34. Comparison of hepatic peroxisome proliferative effect and its implication for hepatocarcinogenicity of phthalate esters, di(2-ethylhexyl) phthalate, and di(2-ethylhexyl) adipate with a hypolipidemic drug.
Reddy JK; Reddy MK; Usman MI; Lalwani ND; Rao MS
Environ Health Perspect; 1986 Mar; 65():317-27. PubMed ID: 3709457
[TBL] [Abstract][Full Text] [Related]
35. Induction of peroxisome proliferation in hepatocytes transplanted into the anterior chamber of the eye. A model system for the evaluation of xenobiotic-induced effects.
Rao MS; Thorgeirsson S; Reddy MK; Lalwani ND; Evarts RE; Usman MI; Singh B; Reddy JK
Am J Pathol; 1986 Sep; 124(3):519-27. PubMed ID: 3532814
[TBL] [Abstract][Full Text] [Related]
36. Role of thyroid state on induction by ciprofibrate of laurate hydroxylase and peroxisomal enzymes in rat liver microsomes.
Pacot C; Charmoillaux M; Goudonnet H; Truchot RC; Latruffe N
Biochem Pharmacol; 1993 Apr; 45(7):1437-46. PubMed ID: 8471068
[TBL] [Abstract][Full Text] [Related]
37. Reduction of rat liver endoplasmic reticulum Ca(2+)-ATPase activity and mobilization of hepatic intracellular calcium by ciprofibrate, a peroxisome proliferator.
Bennett AM; Williams GM
Biochem Pharmacol; 1992 Feb; 43(3):595-605. PubMed ID: 1531754
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in the rat liver.
Lalwani ND; Reddy MK; Qureshi SA; Sirtori CR; Abiko Y; Reddy JK
Hum Toxicol; 1983 Jan; 2(1):27-48. PubMed ID: 6840792
[TBL] [Abstract][Full Text] [Related]
39. An in vitro demonstration of peroxisome proliferation and increase in peroxisomal beta-oxidation system mRNAs in cultured rat hepatocytes treated with ciprofibrate.
Thangada S; Alvares K; Mangino M; Usman MI; Rao MS; Reddy JK
FEBS Lett; 1989 Jul; 250(2):205-10. PubMed ID: 2753129
[TBL] [Abstract][Full Text] [Related]
40. Influence of peroxisome proliferators on phosphoprotein levels in human and rat hepatic-derived cell lines.
Passilly P; Jannin B; Latruffe N
Eur J Biochem; 1995 May; 230(1):316-21. PubMed ID: 7601116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
